September 2017 Europe Supplement

Table of Contents

European Supplement

Drug-Eluting Technologies

Choosing the Best Option Through Data-Informed Decision Making

Sponsored by Boston Scientific Corporation

Issue

SFA

The Forces Driving Care

View Issue

Download PDF

The State of Peripheral Drug‑Eluting Technologies

By Michael R. Jaff, DO

Interim Results From the Muenster Postmarket All-Comers Registry

A look at the latest data on use of the Eluvia drug-eluting stent in challenging SFA lesions.

By Theodosios Bisdas, MD, PhD

Twelve-Month Results From the RANGER-SFA Trial

What these findings tell us about the safety and efficacy of the Ranger drug-coated balloon.

With Dierk Scheinert, MD

Economic Analysis Supporting the Use of Drug-Eluting Technologies in the Femoropopliteal Artery

These evolving modern therapies are showing promise in reducing health care costs while offering better outcomes.

By Konstantinos Katsanos, MSc, MD, PhD, EBIR

Clinical Benefit of Long-Length Drug-Coated Balloons

The anatomic factors that make longer DCBs the ideal choice for treating longer, more difficult lesions.

By Gunnar Tepe, MD

Experience With Atherectomy and DCBs

The merits of a two-part approach in the SFA and popliteal artery.

By Ulrich Sunderdiek, MD, PhD

Experience With Drug-Eluting Technologies in BTK Interventions

Promising results for drug-eluting stent use in CLI patients with lesions below the knee.

By Hans van Overhagen, MD, PhD, EBIR

New Technologies to Solve the Challenges of CLI

The unique features of this disease are finally being addressed with new devices.

By J.A. Mustapha, MD, and Fadi Saab, MD

Latest Issues

April 2026

March 2026

February 2026

January 2026

December 2025

View All Issues